About BrightGene
BrightGene is a publicly listed company based in Suzhou (China) founded in 2001. Pharmaceutical formulations, active ingredients, and veterinary drugs are manufactured. BrightGene has raised $80 million across 2 funding rounds from investors including GF Securities, Highlight Capital Partners and Sequoia Capital. Its website bright-gene.com draws about 35 thousand monthly visits. BrightGene offers products and services including Formulations and Active Pharmaceutical Ingredients. Its focus areas include Traditional Pharmaceuticals and Diversified. Its legal entity in India is εηηη©ε»θ―οΌθε·οΌθ‘δ»½ζιε ¬εΈ (U99999MH1977PLC010754).
Company details
Established in 2001 in Suzhou, China, BrightGene focuses on the pharmaceutical industry. Formulations for human use, active pharmaceutical ingredients, and veterinary drugs are developed and produced. A research and development system is utilized to drive innovation and ensure quality control. Production processes are supported by integrated systems for manufacturing and compliance, with operations centered on pharmaceutical and veterinary sectors.
- Headquarters Suzhou, China
- Stage Public
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website bright-gene.com
- Social LinkedIn
- Legal Name Brightgene Bio-Medical Technology Co. Ltd. Class A
- Annual Revenue$174.26 M (USD)-4.66as on Dec 31, 2025
- Net Profit$7.79 M (USD)-71.18as on Dec 31, 2025
- EBITDA$29.21 M (USD)-34.18as on Dec 31, 2025
- Total Equity Funding$80M (USD)
in 2 rounds
- InvestorsGF Securities
& 2 more
Associated legal entities of BrightGene
BrightGene operates through , (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| , CIN U99999MH1977PLC010754 | Active | 10 Aug 1977 | Nanded, Maharashtra | View details |
Products & Services of BrightGene
BrightGene offers a comprehensive portfolio of products and services, including Formulations and Active Pharmaceutical Ingredients.
Formulations are developed and supplied for medical purposes.
Active pharmaceutical ingredients and intermediates are produced for drug manufacturing.
Funding Insights of BrightGene
BrightGene has successfully raised a total of $80M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $80M
- Total Rounds 2
- First Round $80M
(Jan 2019)
- Investors Count 3
All 2 funding rounds of BrightGene with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2026 | Series A | β | β | β | |
| Jan 2019 | $80M | Series C | β | Highlight Capital Partners, Sequoia Capital China |
3 investors in total: 3 institutional.
Investors in BrightGene
BrightGene has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include GF Securities, Highlight Capital Partners and Sequoia Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| highlightcapitalpartners.com | ||||
Provider of investment & asset management and financial services | 1991 | gf.com.cn | Guangzhou, China | |
Venture capital firm focused on early-stage investments | sequoiacap.cn | Beijing, China |
Investor details for BrightGene
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
IPO & Listings of BrightGene
BrightGene is a publicly listed company on the SSE with ticker symbol 688166 in China, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date31 Oct 2019
- Listed onSSE: 688166
- Listed entityBrightGene Bio-Medical Technology Co. Ltd. Class A
- Exchange sectorHealth technology
- ISINCNE100003PR1
- Share price31.55 CNY (+1.61% on the day) · 2026-10-14
- Market capitalisation13,531,434,834.00 CNY
- Price to earnings140.6
- EPS (diluted, trailing year)0.22 CNY
- Dividend yield0.05%
- Volume (last session)7,442,907
Financials of BrightGene
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 1.22B CNY | 54.5M CNY | 204.5M CNY |
| 2024 | 1.28B CNY | 189.2M CNY | 310.6M CNY |
| 2023 | 1.18B CNY | 202.5M CNY | 288.0M CNY |
| 2022 | 1.02B CNY | 239.6M CNY | 292.1M CNY |
| 2021 | 1.05B CNY | 243.9M CNY | 301.3M CNY |
Balance sheet, profit and loss, cash flow and ratios of , are on its company page.
Detailed financial statements for BrightGene
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of BrightGene
4 dated milestones of BrightGene across 25 years, from founding to its latest funding, stage changes and deals.
- Founded BrightGene is founded.
- Funding First funding round of $80.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Series A,.
Web traffic of BrightGene
The website of BrightGene (bright-gene.com) receives about 34.5K visits a month.
- Monthly visits34.5K
▲ 26157.2% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Brightgene
Complete news archive for BrightGene
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BrightGene
BrightGene was founded in 2001 and raised its 1st funding round 18 years after it was founded.
BrightGene is headquartered in Suzhou, China. It is registered at Suzhou, Jiangsu, China.
BrightGene is a funded company, having raised a total of $80M across 2 funding rounds to date. The company's 1st funding round was a Series C of $80M, raised on Jan 2019.
Annual revenue of BrightGene is $174.26M as on Dec 31, 2025.
Established in 2001 in Suzhou, China, BrightGene focuses on the pharmaceutical industry. Formulations for human use, active pharmaceutical ingredients, and veterinary drugs are developed and produced. A research and development system is utilized to drive innovation and ensure quality control. Production processes are supported by integrated systems for manufacturing and compliance, with operations centered on pharmaceutical and veterinary sectors.
BrightGene offers Formulations and Active Pharmaceutical Ingredients.
Yes, BrightGene is publicly traded on SSE under the ticker symbol 688166.
BrightGene has 3 investors. Key investors include GF Securities, Highlight Capital Partners, and Sequoia Capital.
BrightGene operates through ,.